AJANTPHARM.NS
AJANTPHARM.NS
INE031B01049
AJANTA PHARMA LIMITED
Loading chart...

Company Profile

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Related stocks

IPCALAB.NS
IPCALAB.NS • India
IPCA LABORATORIES LTD
1,915.4 INR
5.02B USD 1Y +43%
GLENMARK.NS
GLENMARK.NS • India
GLENMARK PHARMACEUTICALS
2,293 INR
6.69B USD 1Y +13.6%
ALKEM.NS
ALKEM.NS • India
ALKEM LABORATORIES LTD.
5,279 INR
6.52B USD 1Y -4.4%
ABBOTINDIA.NS
ABBOTINDIA.NS • India
ABBOTT INDIA LIMITED
26,000 INR
5.71B USD 1Y -14.5%
NEULANDLAB.BO
NEULANDLAB.BO • India
NEULAND LABORATORIES LTD.
20,879.85 INR
2.77B USD 1Y +35.8%
EMCURE.NS
EMCURE.NS • India
EMCURE PHARMACEUTICALS L
1,833.5 INR
3.59B USD 1Y +31.4%
PPLPHARMA.NS
PPLPHARMA.NS • India
PIRAMAL PHARMA LIMITED
196.88 INR
2.7B USD 1Y -0.4%
GLAND.NS
GLAND.NS • India
GLAND PHARMA LIMITED
3,061.8 INR
5.22B USD 1Y +57.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
29.0% p.a.
Max Drawdown (5Y)
-30.7%
Sharpe Ratio (5Y)
0.51
Beta Factor
0.22
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (29.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -56.9% in the extended horizon.
ende